Literature DB >> 17291530

Heparin-binding EGF-like growth factor decreases inflammatory cytokine expression after intestinal ischemia/reperfusion injury.

Dorothy V Rocourt1, Veela B Mehta, Gail E Besner.   

Abstract

BACKGROUND: Intestinal ischemia/reperfusion (I/R) injury is believed to be the major initiator of the systemic inflammatory response syndrome. As a result of intestinal I/R, the gut becomes a major source of inflammatory cytokine production. We have previously shown that heparin-binding EGF-like growth factor (HB-EGF) is cytoprotective after intestinal I/R and down-regulates pro-inflammatory cytokine production in vitro. We now examine the effects of HB-EGF on pro-inflammatory cytokine expression in vivo.
MATERIALS AND METHODS: Rats were randomized into three groups: sham-operated, superior mesenteric artery occlusion (SMAO) for 90 min followed by 8 h of reperfusion (I/R), and I/R with intraluminal administration of HB-EGF 25 min after the initiation of ischemia (I/R + HB-EGF). Serum was drawn at 2, 4, 6, and 8 h post reperfusion for determination of cytokine protein levels using a bioplex suspension array system. Additional animals underwent the same ischemic protocol followed by 30 and 60 min of reperfusion with harvesting of ileal mucosa. Ileal pro-inflammatory cytokine gene expression was determined using reverse transcriptase polymerase chain reaction (RT-PCR) with primers specific for TNF-alpha, IL-6, and IL-1beta.
RESULTS: HB-EGF decreased TNF-alpha, IL-6, and IL-1beta serum protein levels at 4, 6, and 8 h after intestinal I/R injury. In addition, HB-EGF decreased local intestinal mucosal mRNA expression of TNF-alpha, IL-6, and IL-1beta 30 and 60 min after intestinal injury.
CONCLUSIONS: We conclude that pro-inflammatory cytokine expression is increased both locally and in the systemic circulation after intestinal I/R and that the administration of HB-EGF significantly reduces intestinal I/R-induced pro-inflammatory cytokine expression in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17291530      PMCID: PMC1905844          DOI: 10.1016/j.jss.2006.10.047

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  28 in total

1.  Isolation and characterization of a macrophage-derived heparin-binding growth factor.

Authors:  G Besner; S Higashiyama; M Klagsbrun
Journal:  Cell Regul       Date:  1990-10

2.  The balance between the production of tumor necrosis factor-alpha and interleukin-10 determines tissue injury and lethality during intestinal ischemia and reperfusion.

Authors:  Danielle G Souza; Mauro M Teixeira
Journal:  Mem Inst Oswaldo Cruz       Date:  2005-06-14       Impact factor: 2.743

3.  Heparin-binding EGF-like growth factor decreases apoptosis in intestinal epithelial cells in vitro.

Authors:  M P Michalsky; A Kuhn; V Mehta; G E Besner
Journal:  J Pediatr Surg       Date:  2001-08       Impact factor: 2.545

4.  Intestinal cytokine response after gut ischemia: role of gut barrier failure.

Authors:  M R Grotz; E A Deitch; J Ding; D Xu; Q Huang; G Regel
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

5.  Intestinal and hemodynamic impairment following mesenteric ischemia/reperfusion.

Authors:  A Khanna; J E Rossman; H L Fung; M G Caty
Journal:  J Surg Res       Date:  2001-07       Impact factor: 2.192

6.  Heparin-binding epidermal growth factor-like growth factor protects rat intestine from ischemia/reperfusion injury.

Authors:  S B Pillai; C E Hinman; M H Luquette; P T Nowicki; G E Besner
Journal:  J Surg Res       Date:  1999-12       Impact factor: 2.192

7.  Heparin-binding EGF-like growth factor decreases inducible nitric oxide synthase and nitric oxide production after intestinal ischemia/reperfusion injury.

Authors:  G Xia; M Lara-Marquez; M H Luquette; S Glenn; A Haque; G E Besner
Journal:  Antioxid Redox Signal       Date:  2001-10       Impact factor: 8.401

8.  Heparin-binding EGF-like growth factor down regulates proinflammatory cytokine-induced nitric oxide and inducible nitric oxide synthase production in intestinal epithelial cells.

Authors:  Maria L Lara-Marquez; Veela Mehta; Marc P Michalsky; James B Fleming; Gail E Besner
Journal:  Nitric Oxide       Date:  2002-03       Impact factor: 4.427

9.  Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced NF-kappa B activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway.

Authors:  Veela B Mehta; Gail E Besner
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

10.  IL-10 is not protective in intestinal ischemia reperfusion injury.

Authors:  Anthony Stallion; Tzuyung D Kou; Kelly A Miller; Beverly B Dahms; David L Dudgeon; Alan D Levine
Journal:  J Surg Res       Date:  2002-06-15       Impact factor: 2.192

View more
  27 in total

1.  Heparin-binding epidermal growth factor-like growth factor restores Wnt/β-catenin signaling in intestinal stem cells exposed to ischemia/reperfusion injury.

Authors:  Chun-Liang Chen; Jixin Yang; Iyore O A James; Hong-Yi Zhang; Gail E Besner
Journal:  Surgery       Date:  2014-02-06       Impact factor: 3.982

2.  Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis.

Authors:  Jixin Yang; Daniel Watkins; Chun-Liang Chen; Bharath Bhushan; Yu Zhou; Gail E Besner
Journal:  J Am Coll Surg       Date:  2012-07-21       Impact factor: 6.113

3.  HB-EGF protects the lungs after intestinal ischemia/reperfusion injury.

Authors:  Iyore A O James; Chun-Liang Chen; Guangcun Huang; Hong-Yi Zhang; Markus Velten; Gail E Besner
Journal:  J Surg Res       Date:  2010-04-24       Impact factor: 2.192

Review 4.  Radiation enteritis.

Authors:  Ali H Harb; Carla Abou Fadel; Ala I Sharara
Journal:  Curr Gastroenterol Rep       Date:  2014

5.  Epidermal growth factor improves survival and prevents intestinal injury in a murine model of pseudomonas aeruginosa pneumonia.

Authors:  Jessica A Dominguez; Paul J Vithayathil; Ludmila Khailova; Christopher P Lawrance; Alexandr J Samocha; Enjae Jung; Ann M Leathersich; W Michael Dunne; Craig M Coopersmith
Journal:  Shock       Date:  2011-10       Impact factor: 3.454

6.  M1 to M2 macrophage polarization in heparin-binding epidermal growth factor-like growth factor therapy for necrotizing enterocolitis.

Authors:  Jia Wei; Gail E Besner
Journal:  J Surg Res       Date:  2015-03-18       Impact factor: 2.192

7.  Intestinal phenotype in mice overexpressing a heparin-binding EGF-like growth factor transgene in enterocytes.

Authors:  Chun-Liang Chen; Veela B Mehta; Hong-Yi Zhang; Dana Wu; Iyore Otabor; Andrei Radulescu; Osama N El-Assal; Jiexiong Feng; Yan Chen; Gail E Besner
Journal:  Growth Factors       Date:  2010-04       Impact factor: 2.511

8.  Heparin-binding EGF-like growth factor is a potent dilator of terminal mesenteric arterioles.

Authors:  Yu Zhou; David Brigstock; Gail E Besner
Journal:  Microvasc Res       Date:  2009-04-21       Impact factor: 3.514

9.  Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis.

Authors:  Jessica A Clark; Heng Gan; Alexandr J Samocha; Amy C Fox; Timothy G Buchman; Craig M Coopersmith
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-01       Impact factor: 4.052

10.  Heparin-binding epidermal growth factor-like growth factor attenuates acute lung injury and multiorgan dysfunction after scald burn.

Authors:  Jeffrey Lutmer; Daniel Watkins; Chun-Liang Chen; Markus Velten; Gail Besner
Journal:  J Surg Res       Date:  2013-06-12       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.